<p>/PRNewswire/ -- Kodiak Sciences Inc.（纳斯达克：KOD）是一家专注于视网膜的前商业生物技术公司，致力于研究、开发和商业化变革性治疗药物，今天宣布完成其之前宣布的 800 万股普通股的承销公开发行，其中包括根据承销商完全行使其购买额外股份的选择权出售的 1,043,478 股，公开发行价格为每股 23.00 美元。Kodiak Sciences 从此次发行中获得的总收益约为 1.84 亿美元，未扣除承销折扣和佣金以及 Kodiak Sciences 应支付的估计发行费用。</p>
<p>摩根大通、杰富瑞、Evercore ISI 和瑞银投资银行担任此次发行的联合账簿管理人。</p>
<p>Kodiak 的董事长兼首席执行官 Victor Perlroth 博士表示：“我们很高兴成功完成此次公开发行，这增强了我们的财务状况，因为我们正在推进 KSI-101、KSI-501 和 tarcocimab 这三项晚期临床资产的重要第三阶段顶线结果。此次交易经过深思熟虑的结构设计，反映了我们对资本形成的严谨态度以及我们对长期股东价值的持续关注。”</p>
<p>上述股份是根据 Kodiak Sciences 之前向证券交易委员会（“SEC”）提交的 S-3 表格的货架注册声明进行发行的，包括基础招股说明书，该注册声明于 2023 年 6 月 2 日获得 SEC 的有效确认。与此次发行相关的最终招股说明书补充及随附招股说明书已向 SEC 提交，并可在 SEC 网站 http://www.sec.gov 上免费获取。与此次发行相关的最终招股说明书补充及随附招股说明书的副本可从以下地址获得：摩根大通证券有限责任公司，注意：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，通过电子邮件联系 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；杰富瑞有限责任公司，注意：股权承销招股说明书部门，520 Madison Avenue，New York，New York 10022，电话：（877）821-7388，或通过电子邮件联系 prospectus_department@jefferies.com；Evercore Group L.L.C.，注意：股权资本市场，55 East 52nd Street，35th Floor，New York，NY 10055，或拨打电话 888-474-0200，或通过电子邮件联系 ecm.prospectus@evercore.com；或瑞银证券有限责任公司，注意：招股说明书部门，瑞银投资银行，11 Madison Avenue，New York，New York 10010，或通过电子邮件联系 ol-prospectus-request@ubs.com。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内出售这些证券的行为，在任何此类州或司法管辖区内，任何此类要约、征求或销售在注册或资格之前均属非法。</p>
<p><strong>关于 Kodiak Sciences Inc.</strong></p>
<p>Kodiak Sciences（纳斯达克：KOD）是一家专注于视网膜的前商业生物技术公司，致力于研究、开发和商业化变革性治疗药物。我们专注于将新科学应用于下一代视网膜药物的设计和制造，以预防和治疗全球失明的主要原因。我们的 ABC®平台利用分子工程将基于蛋白质和基于化学的治疗领域结合在一起，并一直是 Kodiak 发现引擎的核心。我们正在开发三个晚期临床项目的组合。Tarcocimab 和 KSI-501 正在两个面向 BLA 的第三阶段研究中探索视网膜血管疾病。KSI-101 是一种双特异性蛋白，正在两个第三阶段研究中探索与炎症相关的黄斑水肿（MESI）。</p>
<p>Kodiak®、Kodiak Sciences®、ABC™、ABC Platform™和 Kodiak 标志是 Kodiak Sciences Inc.在多个全球司法管辖区注册的商标或商标。</p>
<p>来源：Kodiak Sciences Inc.</p>

<p>Kodiak Sciences Inc. 宣布完成其 1.84 亿美元的公开发行，发行 8,000,000 股普通股，包括承销商对额外股份的完全行使选择权。此次发行增强了 Kodiak 在其 KSI-101、KSI-501 和 tarcocimab 资产的 3 期临床试验中的财务状况。摩根大通、杰富瑞、Evercore ISI 和瑞银投资银行管理了此次发行。该股份是在向美国证券交易委员会（SEC）提交的货架注册声明下发行的</p>

<p>, /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering were approximately $184 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Kodiak Sciences Inc.（纳斯达克：KOD）是一家专注于视网膜的前商业生物技术公司，致力于研究、开发和商业化变革性治疗药物，今天宣布完成其之前宣布的 800 万股普通股的承销公开发行，其中包括根据承销商完全行使其购买额外股份的选择权出售的 1,043,478 股，公开发行价格为每股 23.00 美元。Kodiak Sciences 从此次发行中获得的总收益约为 1.84 亿美元，未扣除承销折扣和佣金以及 Kodiak Sciences 应支付的估计发行费用。</p>
</div><p>J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank acted as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>摩根大通、杰富瑞、Evercore ISI 和瑞银投资银行担任此次发行的联合账簿管理人。</p>
</div><p>Dr. Victor Perlroth, M.D., Chairman and CEO of Kodiak commented, &#34;we are pleased to have successfully completed this public offering, which strengthens our financial position as we execute through important Phase 3 topline readouts for all three of our late-stage clinical assets of KSI-101, KSI-501 and tarcocimab. The transaction was thoughtfully structured, reflecting our disciplined approach to capital formation and our continued focus on long-term shareholder value.&#34;</p>
<div class="lb-trans"><p>Kodiak 的董事长兼首席执行官 Victor Perlroth 博士表示：“我们很高兴成功完成此次公开发行，这增强了我们的财务状况，因为我们正在推进 KSI-101、KSI-501 和 tarcocimab 这三项晚期临床资产的重要第三阶段顶线结果。此次交易经过深思熟虑的结构设计，反映了我们对资本形成的严谨态度以及我们对长期股东价值的持续关注。”</p>
</div><p>The shares described above were offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the &#34;SEC&#34;) and that was declared effective by the SEC on June 2, 2023. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing prospectus_department@jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at ol-prospectus-request@ubs.com.</p>
<div class="lb-trans"><p>上述股份是根据 Kodiak Sciences 之前向证券交易委员会（“SEC”）提交的 S-3 表格的货架注册声明进行发行的，包括基础招股说明书，该注册声明于 2023 年 6 月 2 日获得 SEC 的有效确认。与此次发行相关的最终招股说明书补充及随附招股说明书已向 SEC 提交，并可在 SEC 网站 http://www.sec.gov 上免费获取。与此次发行相关的最终招股说明书补充及随附招股说明书的副本可从以下地址获得：摩根大通证券有限责任公司，注意：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，通过电子邮件联系 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；杰富瑞有限责任公司，注意：股权承销招股说明书部门，520 Madison Avenue，New York，New York 10022，电话：（877）821-7388，或通过电子邮件联系 prospectus_department@jefferies.com；Evercore Group L.L.C.，注意：股权资本市场，55 East 52nd Street，35th Floor，New York，NY 10055，或拨打电话 888-474-0200，或通过电子邮件联系 ecm.prospectus@evercore.com；或瑞银证券有限责任公司，注意：招股说明书部门，瑞银投资银行，11 Madison Avenue，New York，New York 10010，或通过电子邮件联系 ol-prospectus-request@ubs.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内出售这些证券的行为，在任何此类州或司法管辖区内，任何此类要约、征求或销售在注册或资格之前均属非法。</p>
</div><p><strong>About Kodiak Sciences Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Kodiak Sciences Inc.</strong></p>
</div><p>Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI).</p>
<div class="lb-trans"><p>Kodiak Sciences（纳斯达克：KOD）是一家专注于视网膜的前商业生物技术公司，致力于研究、开发和商业化变革性治疗药物。我们专注于将新科学应用于下一代视网膜药物的设计和制造，以预防和治疗全球失明的主要原因。我们的 ABC®平台利用分子工程将基于蛋白质和基于化学的治疗领域结合在一起，并一直是 Kodiak 发现引擎的核心。我们正在开发三个晚期临床项目的组合。Tarcocimab 和 KSI-501 正在两个面向 BLA 的第三阶段研究中探索视网膜血管疾病。KSI-101 是一种双特异性蛋白，正在两个第三阶段研究中探索与炎症相关的黄斑水肿（MESI）。</p>
</div><p>Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.</p>
<div class="lb-trans"><p>Kodiak®、Kodiak Sciences®、ABC™、ABC Platform™和 Kodiak 标志是 Kodiak Sciences Inc.在多个全球司法管辖区注册的商标或商标。</p>
</div><p>SOURCE Kodiak Sciences Inc.</p>
<div class="lb-trans"><p>来源：Kodiak Sciences Inc.</p>
</div>

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares | KOD Stock News

Kodiak Sciences 宣布完成 1.84 亿美元普通股公开发行，其中包括承销商全额行使购买额外股份的选择权 | KOD 股票新闻